Compare Qnity Electronics Inc. Common Stock (Q) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qnity Electronics Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Qnity Electronics Inc. Common Stock trades at $119 (market cap $25.71B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 5.3× Travere Therapeutics Inc. Common Stock's market cap, and Qnity Electronics Inc. Common Stock pays a 0.26% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Qnity Electronics Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| Q | TVTX | |
|---|---|---|
Market Cap | $25.71B | $4.88B |
Volume | 1,883,674 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $175.64 | $67.52 |
52-Week Low | $73.54 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.77B | $5.01B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qnity Electronics (Q) trades at $122.95, down 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $4.75B in 2025, though net income margin is expected to dip in 2026. Recent news highlights product launches in AI data center cooling and advanced packaging, alongside inclusion in the PHLX Semiconductor Index.
The stock presents a mixed outlook: strong analyst consensus (100% buy ratings) and a $180 price target suggest significant upside, but technical weakness and a high P/E ratio of 43.9 pose risks. Key opportunities include AI-driven demand and advanced packaging growth, while risks involve execution in a competitive semiconductor market and potential margin pressure.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Qnity Electronics Inc. Common Stock
Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.
Read more on Q →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
